AbbVie Poised to Expand in Neurobiology with Cerevel Acquisition
Pharmaceutical giant AbbVie Inc. is considering enhancing its neurobiological portfolio as it finalises the acquisition of neurobiotech firm Cerevel Therapeutics. Initially announced in December 2023 for 8.7 billion USD, the acquisition was primarily focused on Cerevel's experimental schizophrenia drug, Emraclidine. This drug represents a new class of psychiatric medications that have recently sparked increased interest within the pharmaceutical industry.
The deal's prospects have been further boosted by promising clinical trial results from Cerevel's Parkinson's disease drug, reinforcing the strategic fit of this acquisition for AbbVie. The company's broad portfolio diversification, consistent dividend payments, and stable positive cash flow make AbbVie's securities attractive to investors.
Examining the technical analysis of AbbVie Inc. (NYSE: ABBV) for potential investment opportunities:
On the Daily (D1) timeframe, the stock has formed a support level at 161.50 USD and resistance at 170.55 USD. The stock is currently in a downtrend within a channel and is nearing the upper boundary of this trend. A breakout above the downtrend line could lead to a break of the resistance and initiate an uptrend. Conversely, if the stock breaks below the support level, the next target could be 151.50 USD.
For traders, purchasing the stock if it breaks the resistance at 170.55 USD could make sense, with a short-term price target set at 182.10 USD. For those looking at a medium-term investment, holding a long position with a target of up to 195.00 USD can be considered.
—
Ideas and other content presented on this page should not be considered as guidance for trading or an investment advice. RoboMarkets bears no responsibility for trading results based on trading opinions described in these analytical reviews.
The material presented and the information contained herein is for information purposes only and in no way should be considered as the provision of investment advice for the purposes of Investment Firms Law L. 87(I)/2017 of the Republic of Cyprus or any other form of personal advice or recommendation, which relates to certain types of transactions with certain types of financial instruments.
Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69.88% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
The deal's prospects have been further boosted by promising clinical trial results from Cerevel's Parkinson's disease drug, reinforcing the strategic fit of this acquisition for AbbVie. The company's broad portfolio diversification, consistent dividend payments, and stable positive cash flow make AbbVie's securities attractive to investors.
Examining the technical analysis of AbbVie Inc. (NYSE: ABBV) for potential investment opportunities:
On the Daily (D1) timeframe, the stock has formed a support level at 161.50 USD and resistance at 170.55 USD. The stock is currently in a downtrend within a channel and is nearing the upper boundary of this trend. A breakout above the downtrend line could lead to a break of the resistance and initiate an uptrend. Conversely, if the stock breaks below the support level, the next target could be 151.50 USD.
For traders, purchasing the stock if it breaks the resistance at 170.55 USD could make sense, with a short-term price target set at 182.10 USD. For those looking at a medium-term investment, holding a long position with a target of up to 195.00 USD can be considered.
—
Ideas and other content presented on this page should not be considered as guidance for trading or an investment advice. RoboMarkets bears no responsibility for trading results based on trading opinions described in these analytical reviews.
The material presented and the information contained herein is for information purposes only and in no way should be considered as the provision of investment advice for the purposes of Investment Firms Law L. 87(I)/2017 of the Republic of Cyprus or any other form of personal advice or recommendation, which relates to certain types of transactions with certain types of financial instruments.
Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69.88% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.